Seung Chan Kim (Hangul: 김승찬; born April 15, 1991) is a South Korean medical scientist and inventor, whose main area of research is biomagnetism domestic core technology. He received the 2009 Talent Award of Korea along with Yuna Kim. Furthermore, he serves as World Talent Exchange and Sharing Organization president. Also, he identified the cancer cell growth inhibition mechanism of magnetic-based cell division difference. Dispersed by the static magnetic field, the core protein GCP3 in spindle formation, during cell division cycle, was identified for the first time in the world. This contributed to establish the scientific basis on the availability to the magnetic field for future anti-cancer therapy. From Harvard MGH research exchanges, the treatment of nerve cell to nerve cell turning the magnetic field grow into the direction perpendicular to the magnetic field that can be used in a certain direction based on research data. These all works gave a basis for cell regeneration. In particular, spinal cord and nerve disorders of synaptic connections mismatch, it is crucial. It developed a first time patented technology uncovering a new era in medical science.
Currently he holds 163 intellectual properties. Various talent sharing donations and volunteering was made through creativity, science and decisive contribution. This applies as well as decisive contribution for strengthening humanity. Based on the Korea Talent Association (대한민국인재연합회), he established international human organizations to United Nations establishing the World TESO(World Talent Exchange and Sharing Organization). Philippines, Canada, Australia and has a major contribution to enhancing the international status of contributions to the scientific talent exchange, with the Republic of Korea. He also holds over 200 patents and worked in translation technology with chairman of Google Inc. Eric Schmidt, by academic exchange translation project. Agreement was achieved to build infrastructures. Recently, the August 2014 the Ebola vaccine was developed by him to the Liberian Government, and its structure is the same as Tekmira's products. This has been alleged that the former public patented technology was spread. It has contributed to the development of public Ebola vaccine. Zmapp was better, however, in the aspect of its effect. In this regard, his cDNA research is performed based for vaccine development in other microorganisms.